{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:14:41Z","timestamp":1790784881005,"version":"4.1.0"},"reference-count":172,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T00:00:00Z","timestamp":1673481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004410","name":"TUBITAK (Turkish Scientific and Technological Council)","doi-asserted-by":"publisher","award":["121C417"],"award-info":[{"award-number":["121C417"]}],"id":[{"id":"10.13039\/501100004410","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Multiple myeloma is a hematological cancer type. For its treatment, Bortezomib has been widely used. However, drug resistance to this effective chemotherapeutic has been developed for various reasons. 2D cell cultures and animal models have failed to understand the MM disease and Bortezomib resistance. It is therefore essential to utilize new technologies to reveal a complete molecular profile of the disease. In this review, we in-depth examined the possible molecular mechanisms that cause Bortezomib resistance and specifically addressed MM and Bortezomib resistance. Moreover, we also included the use of nanoparticles, 3D culture methods, microfluidics, and organ-on-chip devices in multiple myeloma. We also discussed whether the emerging technology offers the necessary tools to understand and prevent Bortezomib resistance in multiple myeloma. Despite the ongoing research activities on MM, the related studies cannot provide a complete summary of MM. Nanoparticle and 3D culturing have been frequently used to understand MM disease and Bortezomib resistance. However, the number of microfluidic devices for this application is insufficient. By combining siRNA\/miRNA technologies with microfluidic devices, a complete molecular genetic profile of MM disease could be revealed. Microfluidic chips should be used clinically in personal therapy and point-of-care applications. At least with Bortezomib microneedles, it could be ensured that MM patients can go through the treatment process more painlessly. This way, MM can be switched to the curable cancer type list, and Bortezomib can be targeted for its treatment with fewer side effects.<\/jats:p>","DOI":"10.3390\/ph16010111","type":"journal-article","created":{"date-parts":[[2023,1,12]],"date-time":"2023-01-12T01:32:26Z","timestamp":1673487146000},"page":"111","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Review on Bortezomib Resistance in Multiple Myeloma and Potential Role of Emerging Technologies"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2928-6474","authenticated-orcid":false,"given":"G\u00fcl","family":"Kozalak","sequence":"first","affiliation":[{"name":"Faculty of Engineering and Natural Science, Sabanc\u0131 University, Istanbul 34956, Turkey"},{"name":"Center of Excellence for Functional Surfaces and Interfaces for Nano Diagnostics (EFSUN), Sabanc\u0131 University, Istanbul 34956, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4668-5036","authenticated-orcid":false,"given":"\u0130smail","family":"B\u00fct\u00fcn","sequence":"additional","affiliation":[{"name":"Faculty of Engineering and Natural Science, Sabanc\u0131 University, Istanbul 34956, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4972-3678","authenticated-orcid":false,"given":"Er\u00e7il","family":"Toyran","sequence":"additional","affiliation":[{"name":"Faculty of Engineering and Natural Science, Sabanc\u0131 University, Istanbul 34956, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6283-6717","authenticated-orcid":false,"given":"Ali","family":"Ko\u015far","sequence":"additional","affiliation":[{"name":"Faculty of Engineering and Natural Science, Sabanc\u0131 University, Istanbul 34956, Turkey"},{"name":"Center of Excellence for Functional Surfaces and Interfaces for Nano Diagnostics (EFSUN), Sabanc\u0131 University, Istanbul 34956, Turkey"},{"name":"Turkish Academy of Sciences (T\u00dcBA), \u00c7ankaya, Ankara 06700, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,1,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","article-title":"Bone marrow niches in haematological malignancies","volume":"20","author":"Bonnet","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/HS9.0000000000000163","article-title":"Insights on Multiple Myeloma Treatment Strategies","volume":"3","author":"Mateos","year":"2019","journal-title":"HemaSphere"},{"key":"ref_3","unstructured":"Institute, N.C. (2022, November 01). Surveillance, Epidemiology, and End Results Program, Available online: https:\/\/seer.cancer.gov\/."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Ito, S. (2020). Proteasome Inhibitors for the Treatment of Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12020265"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.phrs.2016.01.029","article-title":"Oxidative stress and proteasome inhibitors in multiple myeloma","volume":"105","author":"Lipchick","year":"2016","journal-title":"Pharmacol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/bjh.13172","article-title":"Recent advances and future directions in targeting the secretory apparatus in multiple myeloma","volume":"168","author":"Auner","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41408-021-00593-2","article-title":"Oral ixazomib-dexamethasone vs. oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: A randomized Phase 2 trial","volume":"12","author":"Dimopoulos","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_9","first-page":"2615","article-title":"Proteasome inhibitors: A novel class of potent and effective antitumor agents","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1475-2867-5-18","article-title":"Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy","volume":"5","author":"Boccadoro","year":"2005","journal-title":"Cancer Cell Int."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1349-7006.2008.01038.x","article-title":"Bortezomib-induced apoptosis in mature T-cell lymphoma cells partially depends on upregulation of Noxa and functional repression of Mcl-1","volume":"100","author":"Ri","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s13277-012-0386-3","article-title":"The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib","volume":"33","author":"Yerlikaya","year":"2012","journal-title":"Tumor Biol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10529-015-1968-0","article-title":"Endoplasmic reticulum stress and autophagy participate in apoptosis induced by bortezomib in cervical cancer cells","volume":"38","author":"Zhang","year":"2016","journal-title":"Biotechnol. Lett."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00384-010-0939-0","article-title":"Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib","volume":"25","author":"Voutsadakis","year":"2010","journal-title":"Int. J. Colorectal. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/1535-7163.MCT-09-0918","article-title":"Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways","volume":"9","author":"Seki","year":"2010","journal-title":"Mol. Cancer Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1158\/1535-7163.MCT-07-2046","article-title":"Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, nuclear factor-\u03baB and activator protein-1 related mechanisms","volume":"7","author":"Chen","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.cellsig.2012.10.004","article-title":"Bortezomib\/proteasome inhibitor triggers both apoptosis and autophagy-dependent pathways in melanoma cells","volume":"25","author":"Selimovic","year":"2013","journal-title":"Cell. Signal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6091","DOI":"10.1074\/jbc.M109.014092","article-title":"Regulation of endoplasmic reticulum stress-induced cell death by ATF4 in neuroectodermal tumor cells","volume":"285","author":"Armstrong","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1349-7006.2004.tb03200.x","article-title":"Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK\/c-Jun\/AP-1 signaling","volume":"95","author":"Yang","year":"2004","journal-title":"Cancer Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4161\/cbt.10.1.12169","article-title":"Combination effects of bortezomib with gemcitabine and EMAP II in experimental pancreatic cancer","volume":"10","author":"Awasthi","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00109-011-0805-8","article-title":"Bortezomib represses HIF-1\u03b1 protein expression and nuclear accumulation by inhibiting both PI3K\/Akt\/TOR and MAPK pathways in prostate cancer cells","volume":"90","author":"Befani","year":"2012","journal-title":"J. Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1158\/1541-7786.MCR-10-0022","article-title":"Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex","volume":"8","author":"Brooks","year":"2010","journal-title":"Mol. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.6004\/jnccn.2020.7690","article-title":"Underperformance of Contemporary Phase III Oncology Trials and Strategies for Improvement","volume":"19","author":"Shen","year":"2021","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"100014","DOI":"10.1016\/j.ooc.2021.100014","article-title":"Multi-organ-on-chip approach in cancer research","volume":"4","author":"Zuchowska","year":"2022","journal-title":"Organs-on-a-Chip"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Dou, Q.P. (2014). Proteasome Inhibitors and Lessons Learned from Their Mechanisms of Action and Resistance in Human Cancer. Resistance to Proteasome Inhibitors in Cancer: Molecular Mechanisms and Strategies to Overcome Resistance, Springer International Publishing.","DOI":"10.1007\/978-3-319-06752-0"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1158\/0008-5472.CAN-14-3400","article-title":"Metabolic signature identifies novel targets for drug resistance in multiple myeloma","volume":"75","author":"Maiso","year":"2015","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.canlet.2014.03.013","article-title":"Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches","volume":"347","author":"Wu","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1182\/blood.V81.2.490.490","article-title":"P-glycoprotein expression in human plasma cell myeloma: Correlation with prior chemotherapy","volume":"81","author":"Grogan","year":"1993","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1182\/blood.V128.22.5144.5144","article-title":"Effect of Expression of Multidrug Resistance Genes in Newly Diagnosed Multiple Myeloma on the Clinical Course of the Disease","volume":"128","author":"Chernykh","year":"2016","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ccr.2012.12.001","article-title":"NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers","volume":"23","author":"Zhou","year":"2013","journal-title":"Cancer Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"19279","DOI":"10.1016\/S0021-9258(17)30655-5","article-title":"ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. Role of the ATP-dependent transport system for glutathione S-conjugates","volume":"265","author":"Ishikawa","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1124\/mol.109.062364","article-title":"Hepatic Clearance of Reactive Glucuronide Metabolites of Diclofenac in the Mouse Is Dependent on Multiple ATP-Binding Cassette Efflux Transporters","volume":"77","author":"Lagas","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1172\/JCI35067","article-title":"Multidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferation","volume":"118","author":"Sassi","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_34","first-page":"175","article-title":"Expression of human MRP6, a homologue of the multidrug resistance protein gene MRP1, in tissues and cancer cells","volume":"59","author":"Kool","year":"1999","journal-title":"Cancer Res."},{"key":"ref_35","first-page":"2709","article-title":"Efficacy of Multi-Drug Resistance Transporters and Glutathione S-Transferase P-1 at Developing Bortezomib Resistance in Multiple Myeloma Cell Lines","volume":"40","author":"Kozalak","year":"2021","journal-title":"Lat. Am. J. Pharm."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1158\/1078-0432.CCR-08-0442","article-title":"Expression of ABCC-Type Nucleotide Exporters in Blasts of Adult Acute Myeloid Leukemia: Relation to Long-term Survival","volume":"15","author":"Guo","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S0006-2952(98)00240-8","article-title":"Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin","volume":"56","author":"Morrow","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"ref_38","first-page":"2153","article-title":"Identification of glutathione S-transferase \u03c0 1 as a prognostic proteomic biomarker for multiple myeloma using proteomic profiling","volume":"19","author":"Zhao","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1038\/leu.2016.102","article-title":"Proteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolism","volume":"30","author":"Soriano","year":"2016","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3324\/haematol.2012.066175","article-title":"The PI3K\/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma","volume":"98","author":"Manik","year":"2013","journal-title":"Haematologica"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/leu.2011.256","article-title":"Impaired bortezomib binding to mutant \u03b25 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells","volume":"26","author":"Franke","year":"2012","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Suzuki, E., Demo, S., Deu, E., Keats, J., Arastu-Kapur, S., Bergsagel, P.L., Bennett, M.K., and Kirk, C.J. (2011). Molecular mechanisms of bortezomib resistant adenocarcinoma cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0027996"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"104511","DOI":"10.1016\/j.phrs.2019.104511","article-title":"Targeting glucose metabolism to suppress cancer progression: Prospective of anti-glycolytic cancer therapy","volume":"150","author":"Mahmoud","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12185-014-1514-1","article-title":"The impact of C-Myc gene-related aberrations in newly diagnosed myeloma with bortezomib\/dexamethasone therapy","volume":"99","author":"Sekiguchi","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1515\/tjb-2019-0521","article-title":"Inhibition of apoptosis may lead to the development of bortezomib resistance in multiple myeloma cancer cells","volume":"46","author":"Kozalak","year":"2021","journal-title":"Turk. J. Biochem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1034\/j.1600-0609.2002.01549.x","article-title":"Expression of the bcl-2 family of pro- and anti-apoptotic genes in multiple myeloma and normal plasma cells: Regulation during interleukin-6(IL-6)-induced growth and survival","volume":"69","author":"Spets","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4918","DOI":"10.1182\/blood.V114.22.4918.4918","article-title":"miRNA Expression in Multiple Myeloma as Predictive Model of Response to Bortezomib","volume":"114","author":"Neri","year":"2009","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1146\/annurev.pharmtox.45.120403.100037","article-title":"Proteasome inhibition in multiple myeloma: Therapeutic implication","volume":"45","author":"Chauhan","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0305-7372(03)00079-3","article-title":"Rationale for the treatment of solid tumors with the proteasome inhibitor bortezomib","volume":"29","author":"Cusack","year":"2003","journal-title":"Cancer Treat. Rev."},{"key":"ref_51","first-page":"218","article-title":"Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo","volume":"21","author":"Schmidmaier","year":"2006","journal-title":"Int. J. Biol. Markers"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cencini, E., Fabbri, A., Sicuranza, A., Gozzetti, A., and Bocchia, M. (2021). The Role of Tumor-Associated Macrophages in Hematologic Malignancies. Cancers, 13.","DOI":"10.3390\/cancers13143597"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Ahmed, S., Khan, H., Aschner, M., Mirzae, H., K\u00fcpeli Akkol, E., and Capasso, R. (2020). Anticancer Potential of Furanocoumarins: Mechanistic and Therapeutic Aspects. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21165622"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41568-018-0005-8","article-title":"Revisiting the role of ABC transporters in multidrug-resistant cancer","volume":"18","author":"Robey","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5108","DOI":"10.1021\/acs.jmedchem.7b01457","article-title":"Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment","volume":"61","author":"Waghray","year":"2018","journal-title":"J. Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0005-2736(76)90160-7","article-title":"A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants","volume":"455","author":"Juliano","year":"1976","journal-title":"Biochim. Biophys Acta"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41467-019-09312-9","article-title":"Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer","volume":"10","author":"Christie","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_58","first-page":"1","article-title":"ABC transporters as mediators of drug resistance and contributors to cancer cell biology","volume":"26","author":"Fletcher","year":"2016","journal-title":"Drug Resist. Updates Rev. Comment. Antimicrob. Anticancer Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/jpet.111.187542","article-title":"Inactivating PSMB5 Mutations and P-Glycoprotein (Multidrug Resistance-Associated Protein\/ATP-Binding Cassette B1) Mediate Resistance to Proteasome Inhibitors: Ex Vivo Efficacy of (Immuno)Proteasome Inhibitors in Mononuclear Blood Cells from Patients with Rheumatoid Arthritis","volume":"341","author":"Verbrugge","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00280-013-2136-7","article-title":"The interaction of bortezomib with multidrug transporters: Implications for therapeutic applications in advanced multiple myeloma and other neoplasias","volume":"71","author":"Ooi","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_62","first-page":"3458","article-title":"Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues","volume":"61","author":"Maliepaard","year":"2001","journal-title":"Cancer Res."},{"key":"ref_63","first-page":"1","article-title":"Human ABCG2: Structure, function, and its role in multidrug resistance","volume":"3","author":"Mo","year":"2012","journal-title":"Int. J. Biochem. Mol. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3881","DOI":"10.1182\/blood-2005-10-009084","article-title":"ABCG2 expression, function, and promoter methylation in human multiple myeloma","volume":"108","author":"Turner","year":"2006","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nm0695-578","article-title":"The drug resistance-related protein LRP is the human major vault protein","volume":"1","author":"Scheffer","year":"1995","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3892\/ijo.2016.3516","article-title":"Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)","volume":"49","author":"Krishnan","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41598-018-36780-8","article-title":"Lung resistance-related protein (LRP) predicts favorable therapeutic outcome in Acute Myeloid Leukemia","volume":"9","author":"Kulsoom","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3346\/jkms.2006.21.2.253","article-title":"Prognostic Significance of Multidrug Resistance Gene 1 (MDR1), Multidrug Resistance-related Protein (MRP) and Lung Resistance Protein (LRP) mRNA Expression in Acute Leukemia","volume":"21","author":"Huh","year":"2006","journal-title":"J. Korean Med. Sci."},{"key":"ref_69","first-page":"1097","article-title":"Expression and prognostic value of the lung resistance-related protein (LRP) in germ cell testicular tumors","volume":"24","author":"Doleschall","year":"2004","journal-title":"Anticancer Res."},{"key":"ref_70","first-page":"827","article-title":"RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response","volume":"9","author":"Burger","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood.V91.3.1029","article-title":"Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma","volume":"91","author":"Raaijmakers","year":"1998","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1360704","article-title":"Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line","volume":"258","author":"Cole","year":"1992","journal-title":"Science"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2017.01.041","article-title":"Structural Basis of Substrate Recognition by the Multidrug Resistance Protein MRP1","volume":"168","author":"Johnson","year":"2017","journal-title":"Cell"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ejmech.2019.05.027","article-title":"Natural products as multidrug resistance modulators in cancer","volume":"176","author":"Kumar","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_75","first-page":"5130","article-title":"Characterization of Vincristine Transport by the Mr 190,000 Multidrug Resistance Protein (MRP): Evidence for Cotransport with Reduced Glutathione1","volume":"58","author":"Loe","year":"1998","journal-title":"Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/sj.bjp.0702360","article-title":"ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1","volume":"126","author":"Renes","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"7616","DOI":"10.1038\/s41598-020-64400-x","article-title":"Molecular analysis of the massive GSH transport mechanism mediated by the human Multidrug Resistant Protein 1\/ABCC1","volume":"10","author":"Nasr","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_78","first-page":"178","article-title":"Human Multidrug Resistance Protein 7 (ABCC10) Is a Resistance Factor for Nucleoside Analogues and Epothilone B","volume":"69","author":"Xu","year":"2008","journal-title":"Cancer Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1152\/physrev.00037.2005","article-title":"Human multidrug resistance ABCB and ABCG transporters: Participation in a chemoimmunity defense system","volume":"86","author":"Sarkadi","year":"2006","journal-title":"Physiol. Rev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2141.1995.tb05164.x","article-title":"GST-pi and P-170 co-expression in multiple myeloma","volume":"90","author":"Petrini","year":"1995","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/0968-0004(92)90489-V","article-title":"The ATP-dependent glutathione S-conjugate export pump","volume":"17","author":"Ishikawa","year":"1992","journal-title":"Trends Biochem. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7690","DOI":"10.1073\/pnas.92.17.7690","article-title":"Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein","volume":"92","author":"Zaman","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1096\/fasebj.11.7.9212074","article-title":"Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP\/cMOAJ) gene in liver","volume":"11","author":"Keppler","year":"1997","journal-title":"FASEB J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/10409238709082547","article-title":"Enzyme-catalyzed detoxication reactions: Mechanisms and stereochemistry","volume":"22","author":"Armstrong","year":"1987","journal-title":"CRC Crit. Rev. Biochem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.abb.2010.05.012","article-title":"Glutathione transferases and development of new principles to overcome drug resistance","volume":"500","author":"Sau","year":"2010","journal-title":"Arch. Biochem. Biophys."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0169-409X(97)00029-X","article-title":"Inhibitors of glutathione S-transferases as therapeutic agents","volume":"26","author":"Tew","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beha.2012.04.007","article-title":"Proteasome inhibitors in mantle cell lymphoma","volume":"25","author":"Holkova","year":"2012","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Egan, P., Drain, S., Conway, C., Bjourson, A.J., and Alexander, H.D. (2016). Towards Stratified Medicine in Plasma Cell Myeloma. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17101760"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/jclinpath-2015-203414","article-title":"Molecular mechanisms in multiple myeloma drug resistance","volume":"69","author":"Nikesitch","year":"2016","journal-title":"J. Clin. Pathol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.leukres.2017.06.002","article-title":"Targeting autophagy in multiple myeloma","volume":"59","author":"Yun","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1158\/1078-0432.CCR-10-2634","article-title":"Principles and current strategies for targeting autophagy for cancer treatment","volume":"17","author":"Amaravadi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/0008-5472.CAN-08-2839","article-title":"The Role of ATF4 Stabilization and Autophagy in Resistance of Breast Cancer Cells Treated with Bortezomib","volume":"69","author":"Milani","year":"2009","journal-title":"Cancer Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.str.2014.11.019","article-title":"Bortezomib-resistant mutant proteasomes: Structural and biochemical evaluation with carfilzomib and ONX 0914","volume":"23","author":"Huber","year":"2015","journal-title":"Structure"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors\u2014Molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J. Cell. Mol. Med."},{"key":"ref_96","first-page":"3660","article-title":"Down-regulation of the transporter for antigen presentation, proteasome subunits, and class I major histocompatibility complex in tumor cell lines","volume":"58","author":"Johnsen","year":"1998","journal-title":"Cancer Res."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1172\/JCI58414","article-title":"A mutation in the immunoproteasome subunit PSMB8 causes autoinflammation and lipodystrophy in humans","volume":"121","author":"Kitamura","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","article-title":"Molecular basis of clonal evolution in multiple myeloma","volume":"111","author":"Furukawa","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.leu.2401902","article-title":"Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies","volume":"14","author":"Solary","year":"2000","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.18632\/oncotarget.1497","article-title":"Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms","volume":"4","author":"Abdi","year":"2013","journal-title":"Oncotarget"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"14374","DOI":"10.1073\/pnas.202445099","article-title":"Molecular sequelae of proteasome inhibition in human multiple myeloma cells","volume":"99","author":"Mitsiades","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bcp.2008.11.024","article-title":"Cooperation between Apo2L\/TRAIL and bortezomib in multiple myeloma apoptosis","volume":"77","author":"Balsas","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"8574","DOI":"10.18632\/oncotarget.14351","article-title":"FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10","volume":"8","author":"Xie","year":"2017","journal-title":"Oncotarget"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","article-title":"The role of glutathione-S-transferase in anti-cancer drug resistance","volume":"22","author":"Townsend","year":"2003","journal-title":"Oncogene"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"521586","DOI":"10.1155\/2014\/521586","article-title":"MicroRNA: Important Player in the Pathobiology of Multiple Myeloma","volume":"2014","author":"Bi","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"12885","DOI":"10.1073\/pnas.0806202105","article-title":"MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis","volume":"105","author":"Pichiorri","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2011.05.017","article-title":"miR-17-92 cluster microRNAs confers tumorigenicity in multiple myeloma","volume":"309","author":"Chen","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbrc.2011.09.063","article-title":"Overexpression of microRNA-29b induces apoptosis of multiple myeloma cells through down regulating Mcl-1","volume":"414","author":"Zhang","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood-2007-03-081133","article-title":"Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer","volume":"110","author":"Pfeifer","year":"2007","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/intimm\/dxq042","article-title":"MicroRNA 125b inhibition of B cell differentiation in germinal centers","volume":"22","author":"Gururajan","year":"2010","journal-title":"Int. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2018-03-836601","article-title":"Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92","volume":"132","author":"Morelli","year":"2018","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"341430","DOI":"10.1155\/2015\/341430","article-title":"Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma","volume":"2015","author":"Yang","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1158\/1078-0432.CCR-12-0779","article-title":"Dual inhibition of canonical and noncanonical NF-\u03baB pathways demonstrates significant antitumor activities in multiple myeloma","volume":"18","author":"Fabre","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1541-7786.MCR-08-0108","article-title":"Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells","volume":"6","author":"Markovina","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrc2714","article-title":"Environment-mediated drug resistance: A major contributor to minimal residual disease","volume":"9","author":"Meads","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/1476-4598-9-176","article-title":"Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells","volume":"9","author":"Markovina","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/leu.2014.255","article-title":"Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma","volume":"29","author":"Yang","year":"2015","journal-title":"Leukemia"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood-2014-03-562439","article-title":"Bone marrow stromal cell\u2013derived exosomes as communicators in drug resistance in multiple myeloma cells","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2013-02-482919","article-title":"RAR\u03b12 expression confers myeloma stem cell features","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"6037","DOI":"10.1038\/s41467-020-19932-1","article-title":"Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma","volume":"11","author":"Federico","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13045-020-00965-4","article-title":"In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma","volume":"13","author":"Omstead","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jconrel.2017.11.045","article-title":"Enhancing proteasome-inhibitory activity and specificity of bortezomib by CD38 targeted nanoparticles in multiple myeloma","volume":"270","author":"Luderer","year":"2018","journal-title":"J. Control. Release"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"2107883","DOI":"10.1002\/adma.202107883","article-title":"Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing","volume":"34","author":"Qu","year":"2022","journal-title":"Adv. Mater."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1807941","DOI":"10.1002\/adfm.201807941","article-title":"Bortezomib Dendrimer Prodrug-Based Nanoparticle System","volume":"29","author":"Hu","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2018.09.022","article-title":"Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma","volume":"80","author":"Gu","year":"2018","journal-title":"Acta Biomater."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Nigro, A., Frattaruolo, L., Fava, M., De Napoli, I., Greco, M., Comand\u00e8, A., De Santo, M., Pellegrino, M., Ricci, E., and Giordano, F. (2020). Bortezomib-Loaded Mesoporous Silica Nanoparticles Selectively Alter Metabolism and Induce Death in Multiple Myeloma Cells. Cancers, 12.","DOI":"10.3390\/cancers12092709"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1166\/jbn.2008.015","article-title":"Fabrication of Gold Nanoparticle for Potential Application in Multiple Myeloma","volume":"4","author":"Patra","year":"2008","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.2147\/CMAR.S255682","article-title":"Inhibition of Multiple Myeloma Using 5-Aza-2\u2032-Deoxycytidine and Bortezomib-Loaded Self-Assembling Nanoparticles","volume":"12","author":"Che","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00432-021-03854-6","article-title":"Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma","volume":"148","author":"Waldschmidt","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2100884","DOI":"10.1002\/adhm.202100884","article-title":"A 3D-Bioprinted Multiple Myeloma Model","volume":"11","author":"Wu","year":"2022","journal-title":"Adv. Healthc. Mater."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"212749","DOI":"10.1016\/j.bioadv.2022.212749","article-title":"Novel microgel culture system as semi-solid three-dimensional in vitro model for the study of multiple myeloma proliferation and drug resistance","volume":"135","author":"Tolosa","year":"2022","journal-title":"Biomater. Adv."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Li, Y.-R., Yu, Y., Kramer, A., Hon, R., Wilson, M., Brown, J., and Yang, L. (2022). An Ex Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy. Cells, 11.","DOI":"10.3390\/cells11091583"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3250","DOI":"10.1182\/blood-2014-02-558007","article-title":"Investigating osteogenic differentiation in multiple myeloma using a novel 3D bone marrow niche model","volume":"124","author":"Reagan","year":"2014","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1021\/acs.jnatprod.1c00446","article-title":"Structure\u2013Activity Relationships of Withanolides as Antiproliferative Agents for Multiple Myeloma: Comparison of Activity in 2D Models and a 3D Coculture Model","volume":"84","author":"Wijeratne","year":"2021","journal-title":"J. Nat. Prod."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"77326","DOI":"10.18632\/oncotarget.12643","article-title":"A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: Biologic and clinical applications","volume":"7","author":"Jakubikova","year":"2016","journal-title":"Oncotarget"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41598-022-05520-4","article-title":"Microfluidic device engineered to study the trafficking of multiple myeloma cancer cells through the sinusoidal niche of bone marrow","volume":"12","author":"Sui","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"064114","DOI":"10.1063\/1.5112050","article-title":"Mechanical segregation and capturing of clonal circulating plasma cells in multiple myeloma using micropillar-integrated microfluidic device","volume":"13","author":"Ouyang","year":"2019","journal-title":"Biomicrofluidics"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Carreras, P., Gonzalez, I., Gallardo, M., Ortiz-Ruiz, A., and Martinez-Lopez, J. (2020). Droplet Microfluidics for the ex Vivo Expansion of Human Primary Multiple Myeloma Cells. Micromachines, 11.","DOI":"10.3390\/mi11030261"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"11391","DOI":"10.1021\/acs.analchem.7b02351","article-title":"Multiple Myeloma Cell Drug Responses Differ in Thermoplastic vs. PDMS Microfluidic Devices","volume":"89","author":"Moore","year":"2017","journal-title":"Anal. Chem."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/1878-0261.12201","article-title":"Microfluidic enrichment of plasma cells improves treatment of multiple myeloma","volume":"12","author":"Zeng","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1039\/C5IB00071H","article-title":"MicroC(3): An ex vivo microfluidic cis-coculture assay to test chemosensitivity and resistance of patient multiple myeloma cells","volume":"7","author":"Pak","year":"2015","journal-title":"Integr. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"121245","DOI":"10.1016\/j.biomaterials.2021.121245","article-title":"Organ-on-a-chip model of vascularized human bone marrow niches","volume":"280","author":"Glaser","year":"2022","journal-title":"Biomaterials"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Yetisgin, A.A., Cetinel, S., Zuvin, M., Kosar, A., and Kutlu, O. (2020). Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules, 25.","DOI":"10.3390\/molecules25092193"},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Iannazzo, D., Ettari, R., Giofr\u00e8, S., Eid, A.H., and Bitto, A. (2020). Recent Advances in Nanotherapeutics for Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12113144"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e1526","DOI":"10.1002\/wnan.1526","article-title":"Nanotherapeutics for multiple myeloma","volume":"10","author":"Zheleznyak","year":"2018","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnology"},{"key":"ref_148","first-page":"195727","article-title":"Drug solubility: Importance and enhancement techniques","volume":"2012","author":"Savjani","year":"2012","journal-title":"Int. Sch. Res. Not. Pharm."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Barenholz, Y.C. (2021). Doxil\u00ae\u2014The first FDA-approved nano-drug: From an idea to a product. Handbook of Harnessing Biomaterials in Nanomedicine, Jenny Stanford Publishing.","DOI":"10.1201\/9781003125259-16"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: Recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnology"},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Lee, K.H., and Kim, T.H. (2021). Recent Advances in Multicellular Tumor Spheroid Generation for Drug Screening. Biosensors, 11.","DOI":"10.3390\/bios11110445"},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Regmi, S., Poudel, C., Adhikari, R., and Luo, K.Q. (2022). Applications of Microfluidics and Organ-on-a-Chip in Cancer Research. Biosensors, 12.","DOI":"10.3390\/bios12070459"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.trecan.2022.03.006","article-title":"Microfluidics meets 3D cancer cell migration","volume":"8","author":"Mehta","year":"2022","journal-title":"Trends Cancer"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Gharib, G., B\u00fct\u00fcn, \u0130., Muganl\u0131, Z., Kozalak, G., Naml\u0131, \u0130., Sarraf, S.S., Ahmadi, V.E., Toyran, E., van Wijnen, A.J., and Ko\u015far, A. (2022). Biomedical Applications of Microfluidic Devices: A Review. Biosensors, 12.","DOI":"10.3390\/bios12111023"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1182\/blood-2011-10-384347","article-title":"Microscale functional cytomics for studying hematologic cancers","volume":"119","author":"Young","year":"2012","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1080\/02652048.2021.1876175","article-title":"Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics","volume":"38","author":"Mahmoudian","year":"2021","journal-title":"J. Microencapsul."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/s41467-017-01593-2","article-title":"Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation","volume":"8","author":"Cetin","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Sung, H.W., Choi, S.-E., Chu, C.H., Ouyang, M., Kalyan, S., Scott, N., and Hur, S.C. (2022). Sensitizing drug-resistant cancer cells from blood using microfluidic electroporator. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0264907"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1021\/acs.accounts.1c00729","article-title":"Droplet Microfluidics for High-Throughput Analysis of Antibiotic Susceptibility in Bacterial Cells and Populations","volume":"55","author":"Postek","year":"2022","journal-title":"Acc. Chem. Res."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nbt.2989","article-title":"Microfluidic organs-on-chips","volume":"32","author":"Bhatia","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1039\/C9LC00861F","article-title":"Microphysiological heart-liver body-on-a-chip system with a skin mimic for evaluating topical drug delivery","volume":"20","author":"McAleer","year":"2020","journal-title":"Lab Chip"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1039\/C5LC00392J","article-title":"A four-organ-chip for interconnected long-term co-culture of human intestine, liver, skin and kidney equivalents","volume":"15","author":"Maschmeyer","year":"2015","journal-title":"Lab Chip"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1021\/acs.analchem.8b05293","article-title":"Recent Advances in Body-on-a-Chip Systems","volume":"91","author":"Sung","year":"2019","journal-title":"Anal. Chem."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.tips.2020.11.009","article-title":"Organ-on-a-Chip: A New Paradigm for Drug Development","volume":"42","author":"Ma","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"9983","DOI":"10.1021\/ac100806x","article-title":"Micro Total Bioassay System for Ingested Substances: Assessment of Intestinal Absorption, Hepatic Metabolism, and Bioactivity","volume":"82","author":"Imura","year":"2010","journal-title":"Anal. Chem."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"120683","DOI":"10.1016\/j.biomaterials.2021.120683","article-title":"A multi-niche microvascularized human bone marrow (hBM) on-a-chip elucidates key roles of the endosteal niche in hBM physiology","volume":"270","author":"Nelson","year":"2021","journal-title":"Biomaterials"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"2101467","DOI":"10.1002\/adem.202101467","article-title":"Bone-on-a-Chip: A Microscale 3D Biomimetic Model to Study Bone Regeneration","volume":"24","author":"Zampouka","year":"2022","journal-title":"Adv. Eng. Mater."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s44164-021-00004-7","article-title":"A vascularized bone-on-a-chip model development via exploring mechanical stimulation for evaluation of fracture healing therapeutics","volume":"1","author":"Das","year":"2022","journal-title":"Vitr. Model."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/s41551-019-0495-z","article-title":"On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology","volume":"4","author":"Chou","year":"2020","journal-title":"Nat. Biomed. Eng."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/CEOR.S104195","article-title":"Cost-effectiveness of bortezomib for multiple myeloma: A systematic review","volume":"8","author":"Chen","year":"2016","journal-title":"Clin. Outcomes Res."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"Wang, H., Xiao, L., Tao, J., Srinivasan, V., Boyce, B.F., Ebetino, F.H., Oyajobi, B.O., Boeckman, R.K., and Xing, L. (2018). Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10030154"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"12888","DOI":"10.3390\/ijms232112888","article-title":"Patient-Derived Multiple Myeloma 3D Models for Personalized Medicine&mdash; Are We There Yet?","volume":"23","author":"Lopes","year":"2022","journal-title":"Int. J. Mol. Sci."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/1\/111\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:03:49Z","timestamp":1760119429000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/1\/111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,12]]},"references-count":172,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["ph16010111"],"URL":"https:\/\/doi.org\/10.3390\/ph16010111","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,12]]}}}